0 129

Cited 9 times in

A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas

DC FieldValueLanguage
dc.contributor.author김진석-
dc.contributor.author양우익-
dc.date.accessioned2018-05-10T06:40:44Z-
dc.date.available2018-05-10T06:40:44Z-
dc.date.issued2013-
dc.identifier.issn0167-6997-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/158423-
dc.description.abstractBACKGROUND: We performed a phase I study to determine the dose and safety of everolimus as a combination chemotherapy in peripheral T-cell lymphoma (PTCL). METHODS: Four dose levels (2.5 to 10 mg) of everolimus from days 1 to 14 with CHOP (750 mg/m(2) cyclophosphamide, 50 mg/m(2) doxorubicin, and 1.4 mg/m(2) (maximum 2 mg) vincristine on day 1, and 100 mg/day prednisone on days 1 to 5) every 21 days were planned. RESULTS: Fifteen patients newly diagnosed with stage III/IV PTCL were enrolled. One of 6 patients at dose level 2 (5 mg everolimus) had grade 3 hepatotoxicity and 3 of 6 patients at level 3 (7.5 mg everolimus) had grade 4 hematologic toxicities (two grade 4 thrombocytopenia and one grade 4 neutropenia with fever lasting more than 3 days). The recommended dose of everolimus for combination was 5 mg. There were no differences in steady state trough concentrations of everolimus between cycles 1 and 2 for all three dose levels. All evaluable patients achieved response (8 complete and 6 partial). CONCLUSIONS: Everolimus (5 mg) can be safely combined with CHOP leading to a feasible and effective regimen for PTCL. The subsequent phase II is now in progress.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer-
dc.relation.isPartOfINVESTIGATIONAL NEW DRUGS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/administration & dosage*-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/adverse effects-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols/pharmacokinetics-
dc.subject.MESHCyclophosphamide/administration & dosage-
dc.subject.MESHCyclophosphamide/adverse effects-
dc.subject.MESHCyclophosphamide/pharmacokinetics-
dc.subject.MESHDoxorubicin/administration & dosage-
dc.subject.MESHDoxorubicin/adverse effects-
dc.subject.MESHDoxorubicin/pharmacokinetics-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHEverolimus-
dc.subject.MESHHumans-
dc.subject.MESHLymphoma, T-Cell, Peripheral/drug therapy*-
dc.subject.MESHLymphoma, T-Cell, Peripheral/metabolism-
dc.subject.MESHMaximum Tolerated Dose-
dc.subject.MESHPrednisone/administration & dosage-
dc.subject.MESHPrednisone/adverse effects-
dc.subject.MESHPrednisone/pharmacokinetics-
dc.subject.MESHSirolimus/administration & dosage-
dc.subject.MESHSirolimus/adverse effects-
dc.subject.MESHSirolimus/analogs & derivatives*-
dc.subject.MESHSirolimus/pharmacokinetics-
dc.subject.MESHVincristine/administration & dosage-
dc.subject.MESHVincristine/adverse effects-
dc.subject.MESHVincristine/pharmacokinetics-
dc.titleA phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorHye Jin Kang-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorHyeon-Seok Eom-
dc.contributor.googleauthorJooryung Huh-
dc.contributor.googleauthorYoung Hyeh Ko-
dc.contributor.googleauthorJongtae Lee-
dc.contributor.googleauthorDong-Seok Yim-
dc.contributor.googleauthorSoo-Youn Lee-
dc.contributor.googleauthorWeon Seo Park-
dc.contributor.googleauthorWoo Ick Yang-
dc.contributor.googleauthorSeung-Sook Lee-
dc.contributor.googleauthorCheolwon Suh-
dc.contributor.googleauthorWon Seog Kim-
dc.identifier.doi10.1007/s10637-013-0015-z-
dc.contributor.localIdA01017-
dc.contributor.localIdA02300-
dc.relation.journalcodeJ01184-
dc.identifier.eissn1573-0646-
dc.identifier.pmid23975510-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs10637-013-0015-z-
dc.subject.keywordEverolimus-
dc.subject.keywordCHOP-
dc.subject.keywordT-cell lymphoma-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameYang, Woo Ick-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorYang, Woo Ick-
dc.citation.volume31-
dc.citation.number6-
dc.citation.startPage1514-
dc.citation.endPage1521-
dc.identifier.bibliographicCitationINVESTIGATIONAL NEW DRUGS, Vol.31(6) : 1514-1521, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.